Irregular Menses in an Adolescent

Several years after menarche, an adolescent has cycles spaced sixty to one hundred twenty days apart, acne, and increasing facial hair. Training volume has also increased and meals are sometimes skipped. Normal pubertal variability, pregnancy, polycystic ovary syndrome, low energy availability, thyroid disease, hyperprolactinemia, and androgen excess must be assessed without relying on cycle irregularity alone.

Case focus#

The decision is which findings exceed expected post-menarche variability, whether pregnancy or medical instability requires immediate action, and whether persistent hyperandrogenism supports a polycystic ovary syndrome pathway. Pelvic ultrasound should not become a shortcut when adolescent diagnostic criteria and longitudinal evidence remain incomplete.

This analysis concentrates on calibration. It compares plausible explanations, asks which observations genuinely discriminate among them, and keeps the working diagnosis open to revision as new evidence arrives.

Problem representation#

The useful representation is not a label alone. It combines the tempo of the problem, the setting, the physiologic or functional threat, the evidence already available, and the important information that is still missing. For this adolescent menstrual irregularity analysis, the working frame must remain broad enough to compare Pregnancy-related menstrual change, Polycystic ovary syndrome, Functional hypothalamic suppression from low energy availability, Thyroid disease or hyperprolactinemia without allowing a familiar first impression to become an untested conclusion.

The setting materially changes the plan: An adolescent clinic with confidential interviewing, pregnancy testing, endocrine laboratory access, nutrition assessment, pelvic imaging when indicated, and longitudinal follow-up.. Available monitoring, access to consultation, travel time, record continuity, and the reliability of follow-through alter what counts as a safe next step. A plan that is reasonable in a continuously monitored environment may be unsafe when results return after discharge or urgent reassessment is difficult.

Immediate safety priorities#

• Hemodynamic symptoms with heavy bleeding: Syncope, tachycardia, pallor, orthostasis, rapid pad saturation, or large clots suggests clinically important blood loss and requires pregnancy testing, blood count, resuscitation assessment, and bleeding control.
• Positive pregnancy test with pain or bleeding: Pelvic pain, shoulder pain, fainting, or bleeding in pregnancy may signal ectopic pregnancy or pregnancy loss and moves the visit to an urgent pregnancy-location pathway.
• Rapid virilization or markedly elevated androgens: Rapid voice deepening, clitoromegaly, severe temporal hair loss, abrupt muscular change, or a strongly elevated androgen concentration raises concern for an ovarian or adrenal tumor.
• Bradycardia orthostasis or severe nutritional restriction: Low heart rate, orthostatic instability, electrolyte abnormality, hypothermia, syncope, or inability to maintain intake indicates eating-disorder or low-energy medical instability that requires urgent treatment.

These findings are action signals rather than diagnostic shortcuts. They determine the pace of stabilization, consultation, and escalation while the causal analysis continues in parallel.

Prioritized differential diagnosis#

Pregnancy-related menstrual change#

What supports it. Any possibility of sperm exposure, missed contraception, breast symptoms, nausea, or an unexpected cycle gap makes pregnancy the first diagnosis to test regardless of reported regularity.

What argues against it or keeps uncertainty open. A correctly timed negative pregnancy test with no later exposure and a longer history of irregular cycles lowers this explanation.

Discriminating next step. Use confidential urine or serum pregnancy testing, repeat when timing is early, and immediately assess pregnancy location when pain, bleeding, syncope, or examination findings are concerning.

Polycystic ovary syndrome#

What supports it. Persistent irregular cycles beyond expected pubertal maturation together with clinical or confirmed biochemical hyperandrogenism supports polycystic ovary syndrome after mimics are excluded.

What argues against it or keeps uncertainty open. Irregular cycles alone soon after menarche, no hyperandrogenism, substantial energy deficit, or a rapidly virilizing pattern does not meet a stable polycystic ovary formulation.

Discriminating next step. Confirm cycle chronology and persistent androgen excess with an appropriate assay, assess blood pressure and metabolic risk, and exclude thyroid, prolactin, adrenal, pregnancy, and medication causes.

Functional hypothalamic suppression from low energy availability#

What supports it. Weight loss, restrictive intake, high training load, stress, fractures, low energy, bradycardia, and low or normal gonadotropins with reduced estradiol support hypothalamic suppression.

What argues against it or keeps uncertainty open. Clear persistent hyperandrogenism, weight gain with metabolic signs, or a tumor-level androgen concentration points to another mechanism, though low energy and polycystic features can coexist.

Discriminating next step. Assess medical stability, diet, exercise, stress, bone history, and eating-disorder symptoms, then involve adolescent nutrition and mental-health care without making weight restoration a punishment.

Thyroid disease or hyperprolactinemia#

What supports it. Temperature intolerance, weight or bowel change, goiter, galactorrhea, headache, visual symptoms, or a relevant medicine raises thyroid or prolactin probability.

What argues against it or keeps uncertainty open. Normal repeat TSH and prolactin under appropriate conditions with no supporting symptoms makes these less likely as the cause of persistent irregularity.

Discriminating next step. Measure TSH and prolactin, repeat a mild prolactin elevation after reducing stress and reviewing medicines, and obtain pituitary imaging only for persistent significant elevation or mass symptoms.

Nonclassic adrenal hyperplasia or androgen-secreting tumor#

What supports it. Early severe hirsutism, rapid progression, virilization, family pattern, very high testosterone or dehydroepiandrosterone sulfate, or elevated morning 17-hydroxyprogesterone supports an adrenal or tumor pathway.

What argues against it or keeps uncertainty open. Slow mild acne and hair change with modest androgens and no virilization fits polycystic physiology more than a tumor.

Discriminating next step. Obtain properly timed 17-hydroxyprogesterone and high-quality androgen measurements, then use endocrine testing and pelvic or adrenal imaging when the level and tempo justify it.

The differential is ranked but not closed. Probability, consequence of delay, reversibility, and test burden are considered together. A dangerous alternative can deserve early exclusion even when it is not the statistically most likely explanation.

Evidence-gathering strategy#

• Menarche cycle growth and medication timeline. Document age at menarche, every interval and bleed duration, growth curve, weight change, training, stress, contraception, hormones, antipsychotics, supplements, and acne treatments. Interpretation: Long gaps that persist several years after menarche require evaluation. A change tied to weight loss, medicine, or exercise suggests a modifiable contributor.
• Confidential pregnancy and sexual-health assessment. Private history improves accuracy about sexual activity, anatomy, contraception, coercion, pregnancy goals, and infection exposure while preserving adolescent dignity and safety. Interpretation: Pregnancy risk triggers immediate testing; coercion or safety concerns activate protective care; exposed anatomic sites guide infection testing.
• Vital signs nutrition exercise and androgen examination. Orthostasis, heart rate, body-temperature, growth, skin, hair distribution, acne, virilization, thyroid, galactorrhea, and signs of insulin resistance separate instability and endocrine mechanisms. Interpretation: Bradycardia or orthostasis requires urgent nutritional assessment; rapid virilization accelerates tumor evaluation; insulin-resistance findings support metabolic screening.
• Targeted TSH prolactin androgen and metabolic testing. High-quality assays test common mimics and quantify androgen excess; glucose and lipid evaluation follows persistent polycystic features and the adolescent's overall risk. Interpretation: Mild isolated variation is repeated before labeling. Persistent hyperandrogenism supports polycystic assessment, while extreme values redirect to ovarian or adrenal imaging.
• Selective adrenal testing or pelvic imaging. Morning 17-hydroxyprogesterone evaluates nonclassic adrenal hyperplasia; imaging is used for pelvic pain, a mass, pregnancy-location questions, or rapid virilization, not to diagnose adolescent polycystic ovary syndrome by morphology alone. Interpretation: An adnexal mass or adrenal biochemical pattern changes referral urgently. Polycystic ovarian morphology without persistent hyperandrogenism is not sufficient for the diagnosis.

Tests are selected because they can change a decision, not because a broad panel feels comprehensive. Results are interpreted with their timing, pretest probability, measurement limitations, recent treatment, and the possibility that an apparently reassuring value was obtained too early or under the wrong conditions.

Progressive course and interpretation#

A confidential pregnancy test is negative, vital signs are stable, and growth review shows recent weight loss. Persistent biochemical androgen elevation is confirmed with an appropriate assay, while thyroid and prolactin results are unrevealing. Nutrition and training are addressed alongside ongoing assessment rather than forcing an early single-cause label.

The trajectory is evidence. Improvement after an intervention may support a mechanism without proving it, while nonresponse should prompt a check of the diagnosis, delivery of the intervention, timing, adherence, and competing pathology. Discordant data should be explained rather than averaged away.

Management reasoning#

• Stabilize severe bleeding pregnancy complications or nutritional instability. Hemodynamic loss, ectopic concern, electrolyte change, bradycardia, or syncope is treated before long-term cycle classification and may require emergency or inpatient care.
• Restore adequate energy availability when suppressed. Nutrition, training load, stress, bone health, and eating-disorder treatment are coordinated with the adolescent. Vital signs, cycle recovery, fractures, and function are monitored without weight stigma.
• Protect the endometrium during prolonged anovulation. When cycle gaps remain long, discuss hormonal options and contraindications according to pregnancy goals, bleeding, migraine, clot risk, blood pressure, and preferences rather than using contraception as the diagnostic test.
• Treat acne and androgen symptoms around patient goals. Topical, hormonal, and antiandrogen options are selected with pregnancy prevention, potassium or blood-pressure monitoring where needed, and realistic timelines for hair and skin response.
• Use longitudinal criteria before fixing the diagnosis. Record cycles, androgens, nutrition, and symptoms over time because adolescent physiology evolves. Reassess if virilization, pain, bleeding, or metabolic risk changes.

Management remains proportional to severity and uncertainty. It includes explicit monitoring targets, foreseeable adverse effects, and stop or escalation conditions. Exact drug selection, dosing, and procedure details depend on verified individual factors, current local protocols, contraindications, and the responsible treating team; the analytical value here is the decision structure and its guardrails.

Communication and shared decisions#

Speak privately for part of the visit, explain confidentiality and its safety limits, and ask about sexual activity, coercion, pregnancy possibility, eating, exercise, medicines, and gender goals without assumptions. Invite caregiver support only in ways acceptable and safe for the adolescent.

The communication task includes what is known, what remains uncertain, why the next step is recommended, what alternatives exist, and which change should trigger urgent reassessment. Teach-back, qualified interpretation when needed, accessible formats, and a named owner for pending results turn information into a safer plan.

Continuity and safety net#

• Use urgent care for fainting, severe bleeding, positive pregnancy with pain, chest symptoms, profound weakness, bradycardia, confusion, or inability to eat and drink.
• Report rapid voice change, clitoromegaly, severe new hair loss, a pelvic mass sensation, or quickly progressing hirsutism before routine follow-up.
• Repeat a pregnancy test when the first test was early and exposure remains possible, and assign every endocrine result to a clinician rather than the portal alone.
• Protect confidential communication preferences and review who can see portal messages, billing statements, and after-visit summaries.

Follow-through is verified, not assumed. The record should identify who receives each pending result, the time window for reassessment, the contingency if contact fails, and the clinical or functional outcome that will show whether the plan is working.

Equity and systems analysis#

Cost, parental portal access, cultural stigma, sports pressure, and limited gender-affirming care can suppress accurate history or disrupt follow-up. Protect confidential communication, provide affordable tests and menstrual products, and frame nutrition around health and function rather than body size.

Access conditions belong in the causal model. Transportation, medication cost, work schedules, caregiving, health literacy, language, disability access, digital connectivity, and prior experiences of care can alter both the observed presentation and the feasibility of the plan. Addressing those constraints improves diagnostic validity as well as fairness.

Reasoning capabilities demonstrated#

• Interprets irregular cycles by years since menarche, gap length, bleeding severity, hyperandrogenism, nutrition, and pregnancy possibility.
• Conducts a confidential adolescent interview that includes coercion, contraception, gender goals, eating, exercise, and portal privacy.
• Separates polycystic ovary syndrome, low energy availability, thyroid or prolactin disease, adrenal disorders, tumors, and pregnancy.
• Avoids using ovarian morphology alone to diagnose polycystic ovary syndrome during adolescence.
• Builds endometrial, metabolic, bone, nutrition, skin, and mental-health goals into longitudinal care.

Key takeaways#

• Pregnancy testing belongs early in the evaluation even when irregular cycles have occurred before.
• Persistent hyperandrogenism and cycle abnormality, not ultrasound morphology alone, support adolescent polycystic ovary syndrome.
• Bradycardia, orthostasis, rapid virilization, heavy bleeding, and pregnancy pain are urgent branches that override routine cycle follow-up.